Elsa Kalbacher - Concepedia

Author

Elsa Kalbacher

Centre Hospitalier Universitaire de Besançon ORCID

Also Known As

Anne-Claire Hardy-Bessard, E Kalbacher, E. Kalbacher, ELSA KALBACHER, Elsa KALBACHER, Elsa Kalbacher, Florence Joly, Kalbacher Elsa, Kalbacher, Elsa

207

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Universitaire de Besançon Centre Léon Bérard Institut Gustave Roussy Institut Paoli-Calmettes Centre François Baclesse

About

Elsa Kalbacher is an author at Centre Hospitalier Universitaire de Besançon specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	24	1.1K
2	Health Sciences	3	3	332
3	Public Health	3	3	67
4	Emergency Medicine	2	2	27
5	Immunology	1	1	30

Elsa Kalbacher

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study Florence Duffaud, Olivier Mir, Pascaline Boudou‐Rouquette, The Lancet Oncology OncologyAdult PatientsMetronomic TherapyClinical TrialsMetastatic Osteosarcoma	2018	304
Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas Antoîne Italiano, Angela Cioffi, Nicolas Penel, Cancer	2011	151
MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum Bradley J. Monk, Rachel N. Grisham, Susana Banerjee, Journal of Clinical Oncology	2020	144
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer Ignace Vergote, Antonio González‐Martín, Keiichi Fujiwara, New England Journal of Medicine	2024	116
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial Patricia Pautier, Antoîne Italiano, Sophie Piperno‐Neumann, The Lancet Oncology Unresectable LeiomyosarcomaFirst-line TherapySurgical OncologyMalignant DiseaseOpen-label Phase 3	2022	110
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial Roman Rouzier, Sébastien Gouy, Frédèric Selle, European Journal of Cancer	2016	107
Effect on Survival of Local Ablative Treatment of Metastases from Sarcomas: A Study of the French Sarcoma Group Alexander T. Falk, Laurence Moureau-Zabotto, M. Ouali, Clinical Oncology Surgical OncologyMalignant DiseaseLocal Ablative TreatmentMedicineCancer Management	2014	96
Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma Patricia Pautier, Antoîne Italiano, Sophie Piperno‐Neumann, New England Journal of Medicine	2024	68
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group Pierre-Étienne Heudel, Michel Fabbro, C. Roemer-Bécuwe, British Journal of Cancer	2017	64
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial Mansoor Raza Mirza, Benedict B. Benigno, Anne Dørum, Gynecologic Oncology MedicineCancer ManagementGynecologyRecurrent Ovarian CancerPharmacotherapy	2020	51

Page 1